CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 144 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2016. The put-call ratio across all filers is 0.75 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $1,447,000 | -13.4% | 408,792 | -1.1% | 0.00% | 0.0% |
| Q3 2016 | $1,670,000 | -8.6% | 413,285 | -0.7% | 0.00% | 0.0% |
| Q2 2016 | $1,827,000 | +40.0% | 416,213 | +20.6% | 0.00% | 0.0% |
| Q1 2016 | $1,305,000 | -75.0% | 345,135 | +3.6% | 0.00% | -71.4% |
| Q4 2015 | $5,223,000 | +49.4% | 333,113 | +0.4% | 0.01% | +40.0% |
| Q3 2015 | $3,496,000 | -60.4% | 331,682 | -5.2% | 0.01% | -54.5% |
| Q2 2015 | $8,828,000 | +7.4% | 350,049 | +18.7% | 0.01% | 0.0% |
| Q1 2015 | $8,222,000 | +68.3% | 295,023 | +10.2% | 0.01% | +83.3% |
| Q4 2014 | $4,884,000 | +39.4% | 267,643 | -1.0% | 0.01% | +20.0% |
| Q3 2014 | $3,504,000 | -20.3% | 270,402 | +0.4% | 0.01% | -16.7% |
| Q2 2014 | $4,396,000 | -0.5% | 269,379 | +7.8% | 0.01% | 0.0% |
| Q1 2014 | $4,416,000 | -26.5% | 249,940 | +0.7% | 0.01% | -33.3% |
| Q4 2013 | $6,009,000 | -26.6% | 248,183 | +7.4% | 0.01% | -35.7% |
| Q3 2013 | $8,190,000 | +139.7% | 231,165 | +5.6% | 0.01% | +133.3% |
| Q2 2013 | $3,417,000 | – | 218,928 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TSP Capital Management Group, LLC | 813,273 | $3,286,000 | 1.66% |
| RTW INVESTMENTS, LP | 1,243,164 | $5,022,000 | 1.52% |
| Marcus Capital, LLC | 112,200 | $453,000 | 0.44% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 996,178 | $4,024,000 | 0.29% |
| Benchmark Capital Advisors | 67,000 | $271,000 | 0.20% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 360,299 | $1,456,000 | 0.20% |
| COLUMBIA WANGER ASSET MANAGEMENT LLC | 2,907,523 | $11,746,000 | 0.15% |
| Virtus ETF Advisers LLC | 59,537 | $241,000 | 0.12% |
| Bellevue Group AG | 160,000 | $646,000 | 0.12% |
| PDT Partners, LLC | 428,300 | $1,730,000 | 0.10% |